

1 **TITLE:**

2 A comparison of health care worker-collected foam and polyester nasal swabs in convalescent
3 COVID-19 patients

4 **AUTHORS:**

5 Brian Hart PhD¹, Yuan-Po Tu MD², Rachel Jennings PhD¹, Prateek Verma MS¹, Leah R Padgett
6 PhD³, Douglas Rains MA³, Deneen Vojta MD¹, Ethan M Berke MD¹

7 **AFFILIATIONS**

- 8 1. UnitedHealth Group, Research and Development, Minnetonka, MN
9 2. The Everett Clinic, Optum, Everett, WA
10 3. Quantigen, Fishers, Indiana

11 **ACKNOWLEDGMENTS**

12 The authors acknowledge the contributions of James S Elliott and Lauren Kennington from
13 Quantigen, Lindsay Nelson from UnitedHealth Group, and Garrett Galbreath, the health care
14 workers, and staff from The Everett Clinic.

15 **CORRESPONDING AUTHOR**

16 Brian Hart

17 Email: BrianHart@uhg.com

18 **ABSTRACT**

19 **Background:** The exponential growth of COVID-19 cases and testing has created supply
20 shortages at various points in the testing workflow. As of April 15, 2020 FDA recommendations
21 only allowed for the use of nasopharyngeal, flocked mid turbinate, or foam nasal swabs, all of
22 which are in very low supply. Polyester swabs are more readily available and mass producible.
23 We compare the performance of polyester and foam swabs stored in different transport media.

24 **Methods:** Both polyester and foam nasal swabs were collected from convalescent COVID-19
25 patients at a single visit. Using the foam nasal swabs as the comparator, sensitivity of the
26 polyester swabs in each media were calculated, three by three tables were constructed to measure
27 concordance, and cycle threshold (Ct) values were compared.

28 **Findings:** 126 visits had polyester and foam swabs stored in viral transport media (VTM), 51
29 had polyester and foam swabs stored in saline, and 63 had a foam swab in VTM and a polyester
30 swab stored in a dry tube. Using nasal foam swabs as a comparator, polyester nasal swabs had a
31 sensitivity of 86.5% when both samples were stored in VTM, 86.7% when both samples were
32 stored in saline, and 72.4% when the polyester swab was stored dry and the foam swab was
33 stored in VTM. Polyester and foam Ct values from the same visit were correlated, but polyester
34 swabs showed decreased performance for cases with a viral load near the detection threshold
35 and higher Ct values on average.

36 **Interpretation:** Polyester nasal swabs showed a reduction in performance from foam nasal
37 swabs, but may still provide a viable sample collection method given the current supply
38 shortages and public health emergency.

- 39 **Funding:** Laboratory testing was conducted with financial support from Thermo Fisher
40 Scientific.

41 **Introduction:**

42 In the few months since the Centers for Disease Control and Prevention began tracking cases of
43 coronavirus disease 2019 (COVID-19), more than 800,000 people have officially tested positive
44 in the United States alone, resulting in more than 44,000 deaths¹. The exponential spread of SARS-
45 CoV-2 has resulted in an enormous demand for testing for the SARS-CoV-2 virus that causes the
46 disease. This increased demand has put a strain on every level of the system from personal
47 protective equipment (PPE) worn by health care workers while administering the test, to swabs for
48 collecting the samples, to viral transport media (VTM) to store the sample until tested, to
49 laboratory capacity^{2,3,4}. Efforts to provide viable alternatives for each of these supply shortages are
50 crucial to keeping the healthcare workforce safe and the testing throughput high.

51 The shortages of PPE and swabs are driven, in part, because the originally recommended
52 nasopharyngeal (NP) test cannot be self-administered, requiring a change in PPE for each test. A
53 recent study showed that patient-collected foam nasal swabs were comparable to health care
54 worker-collected NP swabs for detecting SARS-CoV-2 virus, providing a safer and less invasive
55 sampling method⁵. These results validate findings for influenza testing^{6,7}. While these results open
56 the possibility of using patient-collected foam nasal swabs for sample collection, reducing the risk
57 of viral exposure for health care workers, several issues remain. In the United States, foam nasal
58 and nylon flocked swabs are not as readily available or mass produced as polyester swabs⁸.
59 Additionally, swabs are typically stored and transported in VTM under refrigeration at or below
60 4°C. With VTM and swab supplies running low, and difficulties in obtaining sufficient
61 refrigeration space for the massive number of samples arriving at the labs to be tested, testing
62 requirements must be reevaluated to see if they can be safely altered^{9,10}. Recent work has shown
63 that saline may be a suitable replacement for VTM¹¹. Since these findings were released, the Food

64 and Drug Administration (FDA) has updated their testing recommendations to allow for a wider
65 variety of substances to be used for viral transport and stabilization and allow for self-collected
66 foam nasal swabs when VTM and NP swabs are not available¹².

67 To address the dwindling supply of recommended swabs, we compared the relative performance
68 of polyester and foam nasal swabs for detecting SARS-CoV-2, stored and transported either in
69 VTM, saline, or in a dry tube.

70 **Methods:**

71 **Population and Sample Collection**

72 Patients who have previously tested positive for SARS-CoV-2 at any site from the original study
73 in Washington state were approached to return for additional testing⁵. A cohort of 63 positive
74 patients returned 7-9, 14-18, and 28-31 days after their initial positive diagnosis for longitudinal
75 sample collection, with swabbing continuing until all results for samples from a single visit were
76 negative. A second cohort consisted of participants who also previously tested positive. They
77 were contacted by ambulatory clinic staff and asked to return for a single visit as soon as
78 possible.

79 People who agreed to participate in either study were consented by medical staff. Participants
80 were evaluated at a designated ambulatory clinic site that only saw patients that were confirmed
81 with a prior positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR)
82 test. Inclusion criteria included a previous positive SARS-CoV-2 test and the ability to consent
83 and agree to participate in the study. People who were not able to demonstrate understanding of
84 the study, not willing to commit to having all samples collected, had a history of nosebleed in the
85 past 24 hours, nasal surgery in the past two weeks, chemotherapy treatment with documented

86 low platelet and low white blood cell counts, or acute facial trauma were excluded from the
87 study. Health care workers used a written consent form to explain the study and give eligible
88 patients the opportunity to decline. This study protocol was deemed to be part of a minimal risk
89 research protocol by the Office of Human Research Affairs at UnitedHealth Group.

90 In the first cohort of 63 SARS-CoV-2 positive individuals, three nasal swabs were collected by a
91 health care worker from each patient: a foam swab and two polyester swabs. Patients born in an
92 odd numbered year first had their left nostril swabbed by the foam swab followed by their right
93 nostril being swabbed by the two polyester swabs. Patients born in an even numbered year had
94 their right nostril swabbed by the foam swab followed by their left nostril being swabbed by the
95 two polyester swabs. The first of the two polyester swabs was stored in VTM and the second
96 stored in a dry plastic tube without VTM. The foam swab was always stored in VTM. The two
97 swabs stored in VTM were refrigerated and sent to a reference laboratory for immediate testing,
98 while the dry polyester swab was stored without refrigeration for four days prior to testing. Due
99 to participant testing constraints, the polyester swab to be stored in a dry tube was not collected
100 from all patients. These swabs will be referred to as the foam, VTM polyester, and dry polyester
101 swabs.

102 Patients in the second cohort were also convalescing from COVID-19. They were recruited
103 immediately after their initial positive test result for SARS-CoV-2. During a single visit
104 (between two and seven days after initial diagnosis), these patients were swabbed twice: once
105 with a polyester swab and once with a foam swab. The order of sample collection was
106 randomized in the same manner as in the first cohort. Both samples were refrigerated at 4°C after
107 storage and tested in a reference laboratory as soon as possible.

108 All nasal swab samples were collected by health care workers in the following manner: 1) gently
109 insert the swab in the vertical position into one nasal passage until there is gentle resistance 2)
110 rotate the swab around the nasal vestibule for 10-15 seconds, 3) repeat in the other nostril, and 3)
111 break off the head of the swab in the storage tube. All samples were marked with a patient study
112 number, the swab type, and the media type if any.

113 RT-PCR was performed by a reference laboratory using the TaqPath™ COVID-19 Combo Kit
114 (ThermoFisher; A47814). Cycle threshold (Ct) values for all samples were reported back to the
115 clinical sites based on three different RNA targets: S Gene, ORF1ab, and N Gene. A higher Ct
116 value corresponds to a lower viral load. Per the reference laboratory standard protocols, a sample
117 was considered positive if two or three Ct values were less than or equal to 37, negative if all
118 three Ct values were greater than 37, and inconclusive otherwise. All inconclusive samples were
119 retested and the results of the retest were used, per manufacturer protocol. While a Ct value of 37
120 was used to determine the clinical results of the test, RT-PCR continued until 40 cycles were
121 completed. Therefore, the maximum Ct value in the data is 40. Foam swabs were stored in 1 mL
122 of VTM or 2 mL of saline and vortexed for three to five seconds. Polyester swabs were stored in
123 3 mL of VTM or 2 mL of saline and vortexed for three to five seconds. Dry polyester swabs
124 were eluted in 1 mL of phosphate-buffered saline and vortexed for 30 seconds followed by a ten
125 minute incubation. Ct values were normalized to estimated 3 mL Ct values to account for the
126 difference in volumes. Specifically, 1Ct was subtracted from all results stored in 2 mL of saline
127 or VTM, and 1.585 Ct was subtracted from polyester results stored in 1 mL. The Ct adjustments
128 assume 90-100% PCR efficiency and follow the formula $2^{-dCt} = F$, where dCt is the necessary
129 Ct adjustment and F is the fold increase in volume.

130 **Statistical Analysis**

131 We report the 3x3 confusion matrix showing the results of the polyester swabs against the results
132 of the foam swabs. We estimate the sensitivity of the polyester swabs using the foam nasal swab
133 as the comparator and report the 95% confidence intervals for the sensitivity estimates. For the
134 purposes of sensitivity calculations, inconclusive results were counted as negatives and foam
135 swabs were used as the comparator group. For each RNA target, we calculated the correlation of
136 the normalized Ct values between the foam and polyester swabs for all pairs where at least one
137 of the Ct values was < 40 , indicating enough of the RNA target was detected to stop the RT-PCR
138 machine short of the maximum Ct value. For the same subset of polyester/foam swab pairs with
139 at least one $Ct < 40$ we also took the difference between the two Ct values and plotted the results
140 in a box plot. Positive difference values indicate a higher Ct (and thus lower viral load) in the
141 polyester samples and negative values indicate a higher Ct in the foam samples. All statistical
142 analysis was performed using R version 3.6.1¹³.

143 **Results:**

144 Of the 63 patients in the first cohort, 29 were positive at the 7-9 day visit, five were positive at
145 the 14-18 day visit, and zero were positive at the 28-31 day visit. One patient's swabs from the
146 28-31 day visit leaked in transport and were not tested. The second cohort consisted of 76
147 participants, of which 51 had their swab samples stored in saline and 26 had their swab samples
148 stored in VTM.

149 Polyester nasal swabs detected four fewer positive cases than foam swabs and had an estimated
150 sensitivity (95% confidence interval) of 86.5% (77.3% - 95.8%) when stored in VTM (Table 1).
151 Additionally, there were eight visits with an inconclusive VTM foam swab and a negative VTM
152 polyester swab, but no visits with an inconclusive VTM polyester swab and a negative VTM
153 foam swab. In saline, the polyester swabs detected two fewer positive cases and had an estimated

154 sensitivity of 86·7% (74·5% - 98·8%) (Table 2). The dry polyester swabs detected five fewer
155 cases than foam swabs in VTM and had an estimated sensitivity of 72·4% (56·1% - 88·7%)
156 (Table 3).

157 Correlations between foam and polyester Ct values were highest in the saline samples, followed
158 by the VTM samples and then the dry polyester versus VTM foam samples (Figure 1). While Ct
159 correlations were highest in saline, the foam Ct value was lower than the polyester Ct value more
160 than 63% of the time for the saline swabs, indicating the increased viral loads estimated using
161 foam swabs (Figure 2). Similar biases toward lower Ct values appeared in the VTM polyester
162 versus VTM foam and dry polyester versus VTM foam comparisons. The tendency toward lower
163 Ct values for foam swabs is also apparent in the paired Ct plots (Figure 3). Figure 3 is further
164 broken out by samples taken less than ten days from symptom onset and samples taken at least
165 10 days from symptom onset in Supplemental Figures 1 and 2.

166 **Discussion:**

167 Direct comparison of foam and polyester nasal swabs stored in VTM, in saline, or dry
168 demonstrated decreased, but potentially adequate performance of polyester swabs. The estimated
169 sensitivity of the polyester swabs was 86·5% and 86·7% in VTM and saline respectively. These
170 calculations were conservative because they counted inconclusive polyester results as negatives
171 for the purposes of sensitivity estimation, although no positive VTM foam swabs had a
172 corresponding inconclusive VTM polyester swab. Additionally, foam nasal swabs do not
173 represent the gold standard testing method, and the sensitivity calculations do not account for
174 cases where the foam swab returned a positive result but the polyester swab did not. It is
175 reasonable to believe these are indeed true positives when viewed in the light that all patients had
176 previously tested positive for SARS-CoV-2.

177 The comparison of polyester and foam swabs did not differ between saline and VTM storage.
178 While the estimated sensitivity above 86% may be deemed sufficient in times of a public health
179 emergency, the strength of the findings is diminished for cases with a viral load near the
180 positive/negative threshold of 37 cycles. This issue can be most clearly seen via the cluster of
181 points along the upper edge of the right hand side of the S Gene and N Gene correlation plots.
182 These points represent cases where foam swabs detected virus and the polyester did not. This
183 finding is also reflected in the eight previously mentioned inconclusive VTM foam results that
184 were negative for the VTM polyester swab. All three polyester versus foam swab comparisons
185 exhibited a tendency for the foam swab to have lower Ct values than the polyester swab,
186 indicating the foam swab's superior ability to detect virus. Despite these reductions in
187 performance, polyester swabs in VTM or saline may be an adequate sample collection method in
188 cases where foam nasal and NP swabs have been entirely exhausted, a situation which exists in
189 many locations.

190 The dry polyester swabs showed poor performance, but were put at a disadvantage by the study
191 design. The degradation in performance of the dry swabs could arise from the lack of transport
192 media, lack of refrigeration, extended time before testing, decreased sample collection due to it
193 being the third swab in a nostril, or a combination of these factors. Dry swabs were only
194 collected for the first follow-up visit in the cohort of 63 patients that also had swabs stored in
195 VTM, resulting in a smaller sample size and different time since symptom onset than the other
196 comparisons. Dry swabs have been found to have high sensitivity in other diagnostic settings and
197 should not be ruled out entirely based on this study¹⁴.

198 The current study has several limitations. All participants were convalescing COVID-19 patients,
199 and the time from first symptoms and first diagnosis to test date varied from test to test. As

200 patients progressed further from their diagnosis date their viral loads dropped, creating more
201 cases where the Ct values were near the border of detection. Other research has suggested viral
202 load may have already peaked at the time of diagnosis followed by a slow decline over time¹⁵.
203 The samples from this study may not be representative of testing in newly infected patients who
204 are seeking their first SARS-CoV-2 test. Additionally, because no NP swabs were obtained for
205 this study, performance of the polyester swab cannot be directly compared to the FDA's
206 preferred swabbing method¹². Although final Ct values were adjusted for varying amounts of
207 transport media, imprecision in these adjustments could alter the VTM polyester versus VTM
208 foam comparison. Finally, the study was not designed to compare the performance of VTM and
209 saline or to estimate an interaction of swab type and transport media type.

210 Despite these limitations, polyester swabs stored in VTM or saline may be a viable sample
211 collection method for COVID-19 testing, especially in light of the shortages of other swab types.
212 The viability of polyester swabs is most clearly demonstrated via the high correlation between
213 polyester and foam Ct values from the same visit. Any recommendation for polyester swab usage
214 should bear in mind that the decrease in performance near the border of detection may lead to
215 false negatives in patients with low viral loads.

216 **Data Sharing Statement:**

217 A deidentified dataset will be provided upon reasonable request to the corresponding author.

218

219 **Table 1:** A 3x3 table of the test results for the foam and polyester nasal samples, both stored in
220 VTM and tested immediately.

Sensitivity (95% CI): 86.5% (77.3%, 95.8%)		VTM Polyester Nasal			Total
		Positive	Negative	Inconclusive	
Foam Nasal in VTM	Positive	45	6	1	52
	Negative	3	63	0	66
	Inconclusive	0	8	0	8
	Total	48	77	1	126

221

222

223 **Table 2:** A 3x3 table of the test results for the foam and polyester nasal samples, both stored in
224 saline and tested immediately.

Sensitivity (95% CI): 86.7% (74.5%, 98.8%)		Saline Polyester Nasal			Total
		Positive	Negative	Inconclusive	
Foam Nasal in Saline	Positive	26	4	0	30
	Negative	2	17	1	20
	Inconclusive	0	1	0	1
Total		28	22	1	51

225

226

227 **Table 3:** A 3x3 table of the test results for the foam nasal swabs stored in VTM and tested
228 immediately compared to polyester nasal samples stored in dry tubes without refrigeration for
229 four days before being tested.


Sensitivity (95% CI): 72.4% (56.1%, 88.7%)		Dry Polyester Nasal			Total
		Positive	Negative	Inconclusive	
Foam Nasal in VTM	Positive	21	5	3	29
	Negative	2	26	2	30
	Inconclusive	1	3	0	4
Total		24	34	5	63

230

231

232


233 **Figure 1:** Plots showing the cycle threshold (Ct) values for each of the three RNA targets and
234 three transport media. The black line represents the best fitting linear regression, the dashed blue
235 line represents a perfect one-to-one relationship.



236

237


238 **Figure 2:** Plots showing the difference in cycle threshold (Ct) of the polyester and foam swabs
239 collected at the same visits. Positive values represent higher Ct values in the polyester swab. The
240 dashed red line represents equivalent Ct values. The percentage of samples for which the foam
241 swab has a lower Ct value is shown below each sub-plot.



242

243

244 **Figure 3:** Paired Ct plots showing the polyester and foam Ct values for each transport media and
245 target gene combination considered. Swabs collected at the same visit are connected by a black
246 line.



248 **REFERENCES:**

- 249 1. Coronavirus Disease 2019 (COVID-19) in the US. *Centers for Disease Control and*
250 *Prevention*, accessed April 23, 2020. [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html)
251 [in-us.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html)
- 252 2. Seelye KQ, Jacobs A, Becker J, Arango T. Doctors and Govenors Vie for Masks in
253 Cloak- and Dagger Deals. *New York Times*. April 20, 2020.
- 254 3. Artenstein AW. In Pursuit of PPE. *New England Journal of Medicine*. 2020 Apr 17:e46.
- 255 4. A joint statement by the Association of State and Territorial Health Officials, Association
256 of Public Health Laboratories, and Council of State and Territorial Epidemiologists.
257 COVID-19 Testing Needs to Be Limited to Priority Groups Until Sufficient Testing
258 Supplies and Personal Protective Equipment is Available Nationwide. Association of
259 State and Territorial Health Officials. March 20, 2020.
- 260 5. Tu YP, Jennings R, Hart B, Cangelosi G, Wood R, Wehber K, Verma P, Vojta D, Berke
261 EM. Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield
262 equivalent sensitivity to health care worker collected nasopharyngeal swabs. medRxiv.
263 2020 March.
- 264 6. Larios OE, Coleman BL, Drews SJ, Mazzulli T, Borgundvaag B, Green K, Study SF,
265 McGeer AJ. Self-collected mid-turbinate swabs for the detection of respiratory viruses in
266 adults with acute respiratory illnesses. *PloS one*. 2011;6(6).
- 267 7. Dhiman N, Miller RM, Finley JL, Sztajnkrzyer MD, Nestler DM, Boggust AJ, Jenkins
268 SM, Smith TF, Wilson JW, Cockerill III FR, Pritt BS. Effectiveness of patient-collected
269 swabs for influenza testing. In *Mayo Clinic Proceedings* 2012 Jun 1 (Vol. 87, No. 6, pp.
270 548-554). Elsevier.

- 271 8. Webber L and Jewett C. Testing Swabs Run In Short Supply As Makers Try To Speed
272 Up Production. NPR. March 18, 2020.
- 273 9. Viral Transport Medium (VTM) Supplies Needed. American Academy of Dermatology.
274 [https://assets.ctfassets.net/1ny4yoiyrqia/5gCfl5bSWjHwl3ZLGEg2Xl/0be62e6c8a876254](https://assets.ctfassets.net/1ny4yoiyrqia/5gCfl5bSWjHwl3ZLGEg2Xl/0be62e6c8a876254b98f55c85c08489a/VTM_Supplies_Needed.pdf)
275 [b98f55c85c08489a/VTM_Supplies_Needed.pdf](https://assets.ctfassets.net/1ny4yoiyrqia/5gCfl5bSWjHwl3ZLGEg2Xl/0be62e6c8a876254b98f55c85c08489a/VTM_Supplies_Needed.pdf)
- 276 10. Perrone M. US virus testing faces new headwind: Lab supply shortages. The Associated
277 Press. March 21, 2020.
- 278 11. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ, Fernholz E, Boerger A,
279 Schuetz AN, Yao JD, Binnicker MJ. Evaluation of saline, phosphate buffered saline and
280 minimum essential medium as potential alternatives to viral transport media for SARS-
281 CoV-2 testing. Journal of clinical microbiology. 2020 Mar 30.
- 282 12. FAQs on Diagnostic Testing for SARS-CoV-2. The Food and Drug Administration,
283 accessed on April 16, 2020. [https://www.fda.gov/medical-devices/emergency-situations-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2)
284 [medical-devices/faqs-diagnostic-testing-sars-cov-2](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2)
- 285 13. R: The R Project for Statistical Computing [Internet]. [cited 2020 Mar 21].
286 (<https://www.r-project.org/>)
- 287 14. Campbell AP, Kuypers J, Englund JA, Guthrie KA, Corey L, Boeckh M. Self-collection
288 of foam nasal swabs for respiratory virus detection by PCR among immunocompetent
289 subjects and hematopoietic cell transplant recipients. Journal of clinical microbiology.
290 2013 Jan 1;51(1):324-7.
- 291 15. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,
292 Jones TC, Vollmar P, Rothe C, Hoelscher M. Virological assessment of hospitalized
293 patients with COVID-2019. Nature. 2020 Apr 1:1-0.